At‐Home Self‐Collection of Pharmacokinetic Data: Design and Results From a Phase 1 Open‐Label Feasibility Trial.

Raoufinia, Arash; Shoaf, Susan E.; Rothman, Brian; Ye, Chelsea; Chung, Chris

Pharmacokinetic (PK) studies pose unique technical challenges. We present the design of a Phase 1, open‐label, fixed‐sequence, PK trial that aimed to compare the timing accuracy of participant‐ versus staff‐collected data, and we provide safety and tolerability outcomes for centanafadine treatment. Healthy adults aged 18‐55 years received a single 100‐mg centanafadine sustained‐release tablet at Visits 1, 2, and 4. PK samples (venous sampling and blood microsampling) and safety assessments (12‐lead electrocardiograms [ECGs] and vital signs) were collected by clinical site staff only at Visit 1. At Visit 2, site staff collected venous blood, and participants obtained blood microsamples, a 6‐lead ECG, and vital signs under staff supervision. At Visit 4, participants obtained blood microsamples, a 6‐lead ECG, and vital signs remotely. The absolute differences between actual and scheduled collection times for PK samples, ECGs, and vital signs are reported descriptively. Of the 20 participants, at least 75% obtained blood microsamples within 10 minutes of the planned nominal time. Absolute differences between actual and scheduled collection times of ECGs and vital signs were small. No adverse events were related to treatment. Overall, results support the feasibility of at‐home collection of PK samples, ECGs, and vital signs.

VITAL signs; CLINICAL pharmacology; BLOOD sampling; ELECTROCARDIOGRAPHY; PHARMACOKINETICS

Clinical Pharmacology in Drug Development, 2025, Vol 14, Issue 1, p11

2160-763X

Academic Journal

10.1002/cpdd.1495